Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Aire-Master of America, Inc.
WARNING LETTER
•Aire-Master of America, Inc.•October 19, 2021

Aire-Master of America, Inc. – FDA Warning Letter, Oct 19, 2021

Record Details

The FDA issued a Warning Letter to Aire-Master of America, Inc. following an October 2021 inspection of their Nixa, Missouri drug manufacturing facility. The letter cited significant Current Good Manufacturing Practice (CGMP) violations (21 CFR parts 210 and 211), rendering drug products adulterated. The firm's response to the Form FDA 483 was deemed inadequate. CGMP violations included: failure to establish scientifically sound laboratory controls and specifications, particularly for water system monitoring and microbiological testing (21 CFR 211.160(b)); inadequate investigation of discrepancies, such as a "fishy" odor complaint in hand sanitizer (21 CFR 211.192); failure to conduct appropriate microbial testing for each drug product batch prior to release (21 CFR 211.165(b)); failure to adequately clean and maintain equipment, specifically using shared equipment for OTC drugs and industrial cleaners without validated cleaning methods (21 CFR 211.67(a)); and failure to conduct identity testing for drug product components, with insufficient methods for glycerin and ethyl alcohol to detect toxic contaminants (21 CFR 211.84(d)(1)). Furthermore, Aire-Master Foaming Hand Sanitizer products were deemed unapproved new drugs, violating sections 505(a) and 301(d) of the FD&C Act, and misbranded under section 502(ee) as they did not meet marketing requirements. The FDA strongly recommended a CGMP consultant. The firm must respond within 15 working days with corrective actions and a prevention plan, or face potential regulatory actions including seizure, injunction, and withholding of approvals or export certificates.

Company
Aire-Master of America, Inc.
Inspection date
October 19, 2021
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations III
People
  • Jeffrey D. Meng (Associate Director)
  • Nicholas F. Lyons (Director of Compliance)
View Company Profile

ID · a03e5708-d216-4f15-b0ec-f709515bb2ae

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.160(b)21 CFR 211.19221 CFR 211.19821 CFR 211.165(b)21 CFR 211.67(a)21 CFR 211.84(d)(1)21 CFR 201.128

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Aire-Master of America, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.